NCT04716686View on ClinicalTrials.gov

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Endometrial CarcinomaSerous Carcinoma
Interventions
DRUG

Niraparib

Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.

Trial Locations (1)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
collaborator

Sun Yat-sen University

OTHER

collaborator

Tongji Hospital

OTHER

collaborator

Women's Hospital School Of Medicine Zhejiang University

OTHER

collaborator

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY

lead

Shandong University

OTHER